Bruchim I - Search Results

1

The insulin-like growth factor-I receptor as an oncogene.

Werner H, Bruchim I. Werner H, et al. Among authors: bruchim i. Arch Physiol Biochem. 2009 May;115(2):58-71. doi: 10.1080/13813450902783106. Arch Physiol Biochem. 2009. PMID: 19485702 Review.

2

Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.

Cohen S, Bruchim I, Graiver D, Evron Z, Oron-Karni V, Pasmanik-Chor M, Eitan R, Bernheim J, Levavi H, Fishman A, Flescher E. Cohen S, et al. Among authors: bruchim i. J Mol Med (Berl). 2013 Mar;91(3):357-68. doi: 10.1007/s00109-012-0946-4. Epub 2012 Sep 28. J Mol Med (Berl). 2013. PMID: 23052480

3

Genome-Wide Analyses Identify Filamin-A As a Novel Downstream Target for Insulin and IGF1 Action.

Aizen D, Pasmanik-Chor M, Sarfstein R, Laron Z, Bruchim I, Werner H. Aizen D, et al. Among authors: bruchim i. Front Endocrinol (Lausanne). 2018 Mar 20;9:105. doi: 10.3389/fendo.2018.00105. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 29615978 Free PMC article.

4

Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways.

Werner H, Sarfstein R, LeRoith D, Bruchim I. Werner H, et al. Among authors: bruchim i. Front Oncol. 2016 Jun 23;6:159. doi: 10.3389/fonc.2016.00159. eCollection 2016. Front Oncol. 2016. PMID: 27446805 Free PMC article. Review.

5

Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway.

Werner H, Meisel-Sharon S, Bruchim I. Werner H, et al. Among authors: bruchim i. Mol Cancer. 2018 Feb 19;17(1):28. doi: 10.1186/s12943-018-0807-z. Mol Cancer. 2018. PMID: 29455671 Free PMC article. Review.

6

Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer.

Achlaug L, Sarfstein R, Nagaraj K, Lapkina-Gendler L, Bruchim I, Dixit M, Laron Z, Yakar S, Werner H. Achlaug L, et al. Among authors: bruchim i. Oncotarget. 2019 Jul 9;10(43):4437-4448. doi: 10.18632/oncotarget.27055. eCollection 2019 Jul 9. Oncotarget. 2019. PMID: 31320996 Free PMC article.

7

The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.

Yahya MA, Sharon SM, Hantisteanu S, Hallak M, Bruchim I. Yahya MA, et al. Among authors: bruchim i. Front Endocrinol (Lausanne). 2018 Jun 5;9:297. doi: 10.3389/fendo.2018.00297. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 29922232 Free PMC article.

8

Proliferative and signaling activities of insulin analogues in endometrial cancer cells.

Aizen D, Sarfstein R, Bruchim I, Weinstein D, Laron Z, Werner H. Aizen D, et al. Among authors: bruchim i. Mol Cell Endocrinol. 2015 May 5;406:27-39. doi: 10.1016/j.mce.2015.02.011. Epub 2015 Feb 16. Mol Cell Endocrinol. 2015. PMID: 25697343

9

IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer.

Bruchim I, Sarfstein R, Reiss A, Flescher E, Werner H. Bruchim I, et al. Cancer Lett. 2014 Oct 1;352(2):214-9. doi: 10.1016/j.canlet.2014.06.013. Epub 2014 Jul 2. Cancer Lett. 2014. PMID: 24997432

10

The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches.

Bruchim I, Sarfstein R, Werner H. Bruchim I, et al. Front Endocrinol (Lausanne). 2014 May 19;5:76. doi: 10.3389/fendo.2014.00076. eCollection 2014. Front Endocrinol (Lausanne). 2014. PMID: 24904527 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results